Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B1SW
|
|||
| Former ID |
DNC001203
|
|||
| Drug Name |
Redoxal
|
|||
| Synonyms |
52962-95-5; MLS000736810; NSC73735; UNII-Q0VK2156M5; N,N'-BIS(o-CARBOXYPHENYL)-o-DIANISIDINE; Q0VK2156M5; SMR000528333; 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid; Benzoic acid, 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-; 2-[4-[4-(2-carboxyanilino)-3-methoxyphenyl]-2-methoxyanilino]benzoic acid; 2-[4-[4-(2-carboxyanilino)-3-methoxy-phenyl]-2-methoxy-anilino]benzoic acid; 2-[(4-{4-[(2-carboxyphenyl)amino]-3-methoxyphenyl}-2-methoxyphenyl)amino]benzoic acid; Mini-antibody(scFv)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2], [3] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H24N2O6
|
|||
| Canonical SMILES |
COC1=C(C=CC(=C1)C2=CC(=C(C=C2)NC3=CC=CC=C3C(=O)O)OC)NC4=CC=CC=C4C(=O)O
|
|||
| InChI |
1S/C28H24N2O6/c1-35-25-15-17(11-13-23(25)29-21-9-5-3-7-19(21)27(31)32)18-12-14-24(26(16-18)36-2)30-22-10-6-4-8-20(22)28(33)34/h3-16,29-30H,1-2H3,(H,31,32)(H,33,34)
|
|||
| InChIKey |
IQZIRNIZQHVBMB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 52962-95-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
115883, 605085, 5976542, 8195248, 11445966, 14834942, 26665141, 43128696, 53205221, 56436881, 57318770, 104353225, 117487065, 118240931, 124953289, 125163702, 126424597, 128207751, 134340230, 134340424, 135029666, 142558186, 152137656, 162093388, 163165249, 179340159, 227902495, 241092866, 241348180, 242153423, 252630903
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem. 2002 Nov 1;277(44):41827-34. | |||
| REF 2 | Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism. FEBS Lett. 2000 Feb 4;467(1):27-30. | |||
| REF 3 | A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002 Jun;8(6):1710-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.